| |
Placebo (n = 195)
|
Duloxetine (n = 191)
|
p Value
|
|---|
|
Age, yr
|
49.5 ± 11.7
|
47.8 ± 12.0
|
0.1373a
|
|
Females
|
164 (84.1)
|
157 (82.2)
|
0.6837
|
|
Weight, kg
|
56.28 ± 10.47
|
58.00 ± 11.23
|
0.1219a
|
|
Height, cm
|
159.61 ± 7.76
|
159.41 ± 7.40
|
0.7922
|
|
Major depressive disorder diagnosis
|
7 (3.6)
|
8 (4.2)
|
0.7980
|
|
Duration of fibromyalgia, yr
|
5.7 ± 6.6
|
5.5 ± 5.9
|
0.6968
|
|
Number of tender points
|
15.5 ± 2.3
|
15.4 ± 2.3
|
0.8740
|
|
BPI average pain score (0–10)
|
6.13 ± 1.35
|
6.05 ± 1.29
|
0.5456
|
|
FIQ total score (0–100)
|
56.82 ± 16.14
|
55.95 ± 16.25
|
0.5950
|
|
BDI-II total score (0–63)
|
14.89 ± 9.62
|
15.34 ± 9.73
|
0.6533
|
-
BDI-II Beck Depression Inventory II, BPI Brief Pain Inventory, FIQ Fibromyalgia Impact Questionnaire
- Values are means ± standard deviation or n (%). Continuous variables were analyzed using Welch’s t test, and categorical variables were analyzed using Fisher’s exact test
-
aStatistically significant at a two-sided significance level of 0.15
